Second-line antiretroviral treatment successfully resuppresses drug-resistant hiv-1 after first-line failure: Prospective cohort in sub-saharan africa

Kim C.E. Sigaloff, Raph L. Hamers, Carole L. Wallis, Cissy Kityo, Margaret Siwale, Prudence Ive, Mariette E. Botes, Kishor Mandaliya, Maureen Wellington, Akin Osibogun, Wendy S. Stevens, Michle Van Vugt, Tobias F. Rinke De Wit, Michèle van Vugt

Research output: Contribution to journalArticleAcademicpeer-review

57 Citations (Scopus)


Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa. In adults who switched to boosted protease inhibitor-based regimens after first-line failure, HIV-RNA and genotypic resistance testing was performed at switch and after 12 months. Factors associated with treatment failure were assessed using logistic regression. Of 243 participants, 53 were predicted to receive partially active second-line regimens due to drug resistance. The risk of treatment failure was, however, not increased in these participants. In this African cohort, boosted protease inhibitors successfully resuppressed drug-resistant HIV after first-line failure.

Original languageEnglish
Pages (from-to)1739-1744
Number of pages6
JournalJournal of infectious diseases
Issue number11
Publication statusPublished - 1 Jun 2012

Cite this